DHODH and mesothelioma: Importantly, primary-derived xenograft (PDX) mesothelioma models with inherent NF2 deficiency exhibited a stronger response to DHODH inhibition compared to NF2-intact group, further underscoring the therapeutic vulnerability of NF2-deficient PM (Figs. 6E–G and  EV7G,H).